Viking Therapeutics to Present at Three Major Healthcare Conferences in September
Event summary
- Viking Therapeutics will participate in three investor conferences in September 2026, including fireside chats and investor meetings.
- The conferences are the Cantor Global Healthcare Conference (Sept. 9-11), Morgan Stanley Global Healthcare Conference (Sept. 14-16), and Bernstein Healthcare Forum (Sept. 23-24).
- Viking's lead program, VK2735, is in Phase 3 clinical trials for obesity, with both subcutaneous and oral formulations in development.
- The company is also advancing other obesity programs, including VK3019 and VK2809, and VK0214 for X-linked adrenoleukodystrophy (X-ALD).
The big picture
Viking Therapeutics' participation in these high-profile conferences underscores its focus on engaging with investors as it advances its obesity and metabolic disease pipeline. The company's lead program, VK2735, is a key differentiator in a competitive landscape, with both subcutaneous and oral formulations aiming to address long-term weight management. The strategic emphasis on investor outreach suggests a push to build momentum ahead of potential pivotal trial readouts.
What we're watching
- Clinical Progress
- How the Phase 3 trials for VK2735 will progress and whether the data supports its dual formulation strategy.
- Investor Sentiment
- The impact of Viking's conference presentations on investor confidence and stock performance.
- Competitive Positioning
- Whether Viking can differentiate itself in the crowded obesity treatment market with its pipeline.